Source link : https://www.newshealth.biz/health-news/flot-bests-cross-in-resectable-esophageal-cancer/
Findings from the phase 3 ESOPEC trial demonstrate an overall survival advantage with a perioperative chemotherapy regimen known as FLOT compared with a neoadjuvant chemoradiation approach, called CROSS, in patients with resectable, locally advanced esophageal adenocarcinoma. The study results, presented as a late-breaking abstract at the American Society of Clinical Oncology (ASCO) annual conference, help […]
Author : News Health
Publish date : 2024-06-12 12:39:41
Copyright for syndicated content belongs to the linked Source.
Categories